DB:1YG

Stock Analysis Report

Executive Summary

Immunicum AB (publ) develops therapeutic cancer vaccines.


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has Immunicum's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1YG's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-8.1%

1YG

-4.1%

DE Biotechs

-5.7%

DE Market


1 Year Return

19.0%

1YG

3.7%

DE Biotechs

6.1%

DE Market

Return vs Industry: 1YG exceeded the German Biotechs industry which returned 3.7% over the past year.

Return vs Market: 1YG exceeded the German Market which returned 6.1% over the past year.


Shareholder returns

1YGIndustryMarket
7 Day-8.1%-4.1%-5.7%
30 Day-9.9%-8.2%-5.7%
90 Day0.5%-2.0%-3.6%
1 Year19.0%19.0%4.0%3.7%9.3%6.1%
3 Yearn/a38.2%36.7%8.9%-0.7%
5 Yearn/a9.9%7.5%13.6%-2.0%

Price Volatility Vs. Market

How volatile is Immunicum's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Immunicum undervalued compared to its fair value and its price relative to the market?

3x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 1YG's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 1YG's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 1YG is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 1YG is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1YG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1YG is good value based on its PB Ratio (3x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Immunicum forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

4.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1YG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1YG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1YG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1YG's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 1YG's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 1YG's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Immunicum performed over the past 5 years?

-27.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1YG is currently unprofitable.

Growing Profit Margin: 1YG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1YG is unprofitable, and losses have increased over the past 5 years at a rate of -27.9% per year.

Accelerating Growth: Unable to compare 1YG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1YG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 1YG has a negative Return on Equity (-49.13%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Immunicum's financial position?


Financial Position Analysis

Short Term Liabilities: 1YG's short term assets (SEK303.6M) exceed its short term liabilities (SEK30.2M).

Long Term Liabilities: 1YG's short term assets (SEK303.6M) exceed its long term liabilities (SEK849.0K).


Debt to Equity History and Analysis

Debt Level: 1YG's debt to equity ratio (0.3%) is considered satisfactory.

Reducing Debt: 1YG's debt to equity ratio has reduced from 1% to 0.3% over the past 5 years.


Balance Sheet

Inventory Level: 1YG has a low level of unsold assets or inventory.

Debt Coverage by Assets: 1YG's debt is covered by short term assets (assets are 357.1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1YG has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 1YG has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Immunicum's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.8%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 1YG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 1YG's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1YG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1YG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1YG's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Alex Karlsson-Parra (69yo)

0.2yrs

Tenure

0

Mr. Alex Karlsson-Parra, M.D., Ph.D. is the Founder of Immunicum AB and has been its Chief Scientific Officer since 2008. He serves as Acting Chief Executive Officer at Immunicum AB (publ) since December 1 ...


Leadership Team

NamePositionTenureCompensationOwnership
Per-Olof Gunnesson
Advisor Contracts4yrskr161.70kno data
Alex Karlsson-Parra
Founder0.2yrsno data0.67% SEK520.9k
Michaela Gertz
Chief Financial Officer2yrsno data0.023% SEK17.6k
Sijme Zeilemaker
COO & Senior Director of Business Development0.2yrsno data0.014% SEK11.1k
Margareth Jorvid
Head of Regulatory affairs & QA4.1yrsno data0.032% SEK24.7k
Sharon Longhurst
Head of CMC2.3yrsno data0.0092% SEK7.1k

2.2yrs

Average Tenure

63.5yo

Average Age

Experienced Management: 1YG's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Gunnar Magnus Severus Persson
Independent Director4.2yrskr68.75kno data
Charlotte Edenius
Independent Director3.3yrskr37.50k0.0043% SEK3.4k
Michael S. Oredsson
Chairman1.8yrsno data0.019% SEK14.7k
Steven Glazer
Independent Director3.3yrskr43.75kno data
Kerstin Strinnholm
Independent Director3.3yrskr31.25kno data
Inge Svane
Member of Scientific Advisory Board1.4yrsno datano data
Pawel Kalinski
Member of Scientific Advisory Board1.4yrsno datano data

3.3yrs

Average Tenure

59yo

Average Age

Experienced Board: 1YG's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 1YG insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 73.9%.


Top Shareholders

Company Information

Immunicum AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Immunicum AB (publ)
  • Ticker: 1YG
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr817.402m
  • Listing Market Cap: kr77.300m
  • Shares outstanding: 92.26m
  • Website: https://immunicum.se

Number of Employees


Location

  • Immunicum AB (publ)
  • Östermalmstorg 5
  • Stockholm
  • Stockholm County
  • 114 42
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IMMUOM (OMX Nordic Exchange Stockholm)YesOrdinary SharesSESEKApr 2013
1YGDB (Deutsche Boerse AG)YesOrdinary SharesDEEURApr 2013
IMMUSBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBSEKApr 2013

Biography

Immunicum AB (publ) develops therapeutic cancer vaccines. Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer; and Phase Ib/II clinical trials for the treatment of head and neck cancer, non-small cell lung cancer, and gastric cancer, as well as is in a Phase I/II clinical trials to treat liver cancer and gastrointestinal stromal tumors. The company’s products also comprise IMM-2 platform, which is in preclinical trials is transfected with an adenoviral vector to deliver tumor antigens directly to the cells; and IMM-3 platform, which is in a preclinical phase study optimized CAR-T expansion protocol for improved anti-cancer activity. Immunicum AB (publ) has a collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate ilixadencel in combination with avelumab in multi-indication Phase Ib/II study. The company is headquartered in Stockholm, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 23:37
End of Day Share Price2020/02/25 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.